Verrica Pharmaceuticals   Verrica Pharmaceuticals (VRCA) is a dermatology therapeutics company developing medications for skin diseases.  Today Verrica announced financial results for the fourth quarter and year ended December 31, 2023. Ted White, Verrica Pharmaceuticals' President and Chief Executive Officer said, “We continued to make considerable progress with the launch of YCANTHTM during our first full quarter of commercial operations. With a growing confidence . …

Krystal Biotech Today, February 26, 2024, Krystal Biotech (KRYS) firm announces its full year financial results and business updates.  Read this press release to learn about the company. New England Journal of Medicine publication of the use of B-VEC eyedrop formulation. Reached alignment with FDA to enable approval of B-VEC eyedrop formulation . . . This content is for paid subscribers. Please click here to subscribe …

Vertex Pharmaceuticals in the NEWS Vertex Pharmaceuticals (VRTX) announced that the European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for the label expansion of KALYDECO ® (ivacaftor) for the treatment of infants with cystic fibrosis (CF) ages 1 month to less than 4 months old who have one of the . . . This content is for …

CRISPR Therapeutics Since its inception over a decade ago, CRISPR Therapeutics (CRSP) has transformed from a research-stage company advancing programs in the field of gene editing, to a company with a diverse portfolio of product candidates across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, cardiovascular and rare diseases. The Nobel Prize-winning CRISPR science has revolutionized biomedical research and represents . . …

Ionis Pharmaceuticals  For three decades, Ionis Pharmaceuticals (IONS) invented medicines to treat serious diseases. Currently, Ionis has five marketed products and a wealthy pipeline in neurology, cardiology, and other areas of high patient need. Ionis is a pioneer in RNA-targeted therapeutics. It continues to drive innovation . . . This content is for paid subscribers. Please click here to subscribe or here to log in.

Travere Therapeutics in the NEWS Yesterday, Feb. 15, 2024,  Travere Therapeutics, Inc. (TVTX) reported its fourth quarter and full year 2023 financial results and provided a corporate update. Eric Dube, Ph.D., president and chief executive officer of Travere Therapeutics said, “With ongoing growth in demand for FILSPARI in IgAN and the initiation of the pivotal Phase 3 program of pegtibatinase in classical . . . …

Precision BioSciences Receives Pre-IND Feedback from US FDA for PBGENE-HBV as it Advances Towards Clinical Readiness Precision BioSciences (DTIL) is an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and elimination . . . This content is for paid subscribers. Please click here to subscribe or here to log in.

CRISPR Therapeutics Announcement Today, Feb. 15, 2024, CRISPR Therapeutics announced that members of its senior management team will present at the Citi 2024 Virtual Oncology Leadership Summit on Wednesday, Feb 21, 2024, at 1:00 p.m. ET. A live webcast of the fireside chat will be available on Events & Presentations page in the Investors section of the Company's website. A replay of the webcast will …

Crispr Therapeutics First NEWS As we learned from Vertex Pharmaceuticals (VRTX) in an earlier, posted press release about the European approval, Crispr Therapeutics (CRSP) has also announced the same breakthrough . . . This content is for paid subscribers. Please click here to subscribe or here to log in.

European Commission Grants Conditional Marketing to Vertex Pharmaceuticals CASGEVY Tuesday Feb 13, 2024, Vertex Pharmaceuticals (VRTX) announced that the European Commission has granted conditional marketing authorization to CASGEVY (exagamglogene autotemcel ), a CRISPR/Cas9 gene-edited therapy. CASGEVY is being approved for patients 12 years of age and older with severe sickle cell disease (SCD) characterized by recurrent vaso . . . This content is for paid …

Regenxbio Product RGX-121 Achieves Primary Endpoint From Regenxbio (RGNX) we learned that results from the Phase I/II/III CAMPSIITE® trial of the firm’s product RGX-121 for the treatment of 5 years old patients diagnosed with Mucopolysaccharidosis Type II (MPS II), also known as Hunter syndrome, demonstrated that the pivotal phase of the trial met its primary . . . This content is for paid subscribers. Please …

Madrigal Pharmaceuticals Publication in the New England Journal of Medicine Resmetirom is the first investigational medicine for NASH to achieve fibrosis improvement and NASH resolution primary endpoints in a Phase 3 trial Detailed analyses reinforce the safety profile of resmetirom Resmetirom has the potential to become the first and only medicine approved for NASH; PDUFA date is March 14, 2024 Today, February 8, 2024, Madrigal …

MiNK Therapeutics in the NEWS  Today, February 6, 2024, MiNK Therapeutics (INKT) announced the publication of the results in Nature Communications from phase 1/2 study of agenT-797 . . . This content is for paid subscribers. Please click here to subscribe or here to log in.

Vera Therapeutics to Participate in Guggenheim Healthcare Talks February 2, 2024, Vera Therapeutics, Inc. (VERA) announced that the Company’s management team will participate in the 6th Annual Guggenheim Biotechnology Conference, which is taking place in New York in February 7and Feb 8. Fireside Chat Details: Date: Wednesday, February 7th at 2:00 PM ET The . . . This content is for paid subscribers. Please click here …

Intellia Therapeutics in the NEWS Yesterday, January 31, Intellia Therapeutics (NTLA) announced that the results from Phase 1 portion of the Phase 1/2 study of NTLA-2002 were published online in the New England Journal of Medicine (

Abbott Laboratories New PROTALITY™ for Maintaining Muscle Mass During Weight Loss Abbott Laboratories (ABT) announced the launch of its new PROTALITY™ brand. The high-protein nutrition shake is the first product to support the adults interested in pursuing weight loss while maintaining muscle mass and good nutrition. Half of U.S. adults attempted to lose weight in the past year.  Whether pursuing weight loss by taking GLP-1 medications, …